RecruitingPhase 1Phase 2NCT06207305
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
Sponsor
M.D. Anderson Cancer Center
Enrollment
39 participants
Start Date
Jan 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Dexamethasone, a drug called Diphenhydramine, and others for people with intraperitoneal paclitaxel and metastatic appendiceal adenocarcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDexamethasone
Given by PO
DRUGDiphenhydramine
Given by PO
DRUGFamotidine
Given by PO
DRUGPaclitaxel
Given by PO
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06207305